Syros Pharmaceuticals Cultura de la Empresa

Dr. Nathanael S. Gray, Ph.D., is the founder of C4 Therapeutics, Inc. Dr. Gray Co-Founded Petra Pharma Corporation in 2016 and has been its Chairman of Scientific Advisory Board and Member of Scientific Advisory Board since July 27, 2017. Dr. Gray is the Scientific Founder of Syros Pharmaceuticals, Inc. Dr. Gray serves as an Assistant Professor in the Department of Cancer Biology at the Dana Farber Cancer Research Institute with a joint appointment in the Department of Biological Chemistry and Molecular Pharmacology at Harvard Medical School. He was Co-founder of Syros Pharmaceuticals, Inc. Prior to joining the faculty at Harvard Medical School, Dr. Gray served as The Director of Biological Chemistry at the Genomics Institute of the Novartis Research Foundation (GNF). He was Group Leader at Novartis. He is Principal Investigator of Dana-Farber Cancer Institute, Professor of Biological Chemistry and Molecular Pharmacology, Harvard Medical School. He has been Member of Scientific Advisory Board at C4 Therapeutics, Inc. since November 17, 2016. He has been a Member of Scientific Advisory Board at Syros Pharmaceuticals, Inc since April 2013. He served as a Member of Advisory Board of The Assay Depot Inc., since September 2008. Dr. Gray received both his BS degree and his PhD from the University of California, Berkeley.

Mr. Gerald E. Quirk, J.D., Esq., has been Chief Legal and Administrative Officer of Syros Pharmaceuticals, Inc. since September 26, 2016. Mr. Quirk has broad management responsibility for all legal aspects of the business, including corporate and securities law, intellectual property matters, business development transactions and compliance. Mr. Quirk served as an Executive Vice President of Business Operations and General Counsel at Tokai Pharmaceuticals, Inc. since May 26, 2015 until August 31, 2016. Mr. Quirk has more than twenty years of experience advancing the legal and business interests of public biopharmaceutical companies, including the development and commercialization of oncology products, representing biotechnology companies in connection with securities offerings and SEC compliance activities, mergers and acquisitions, licensing and collaboration agreements and product commercialization initiatives. He was a Partner of Choate, Hall & Stewart LLP. He served as Vice President and General Counsel of Infinity Pharmaceuticals, Inc. since September 21, 2006. Mr. Quirk served in a number of progressively responsible legal and business development positions at Genzyme Corporation, responsible for the provision of all non-patent legal services to Genzyme's oncology, Biosurgery and cardiovascular divisions. Mr. Quirk started his career as an Associate in the business law department and biotechnology practice group at Palmer & Dodge LLP. He served as Co-Chair of Life Sciences Group at Choate, Hall & Stewart LLP since September 2012. He earned his JD from Northeastern University School of Law in 1994, an Ed.M. in Educational Administration from Harvard University in 1991 and a B.A. in Political Science from Swarthmore College in 1989.

Dr. Richard A. Young, also known as Rick, PhD is a Professor of Biology for Massachusetts Institute of Technology. Dr. Young serves as an Advisor to Science magazine, the National Institutes of Health and the World Health Organization. He is a Scientific Founder of Syros Pharmaceuticals. He has been Director at Syros Pharmaceuticals, Inc since November 2011 and has been its Member of Scientific Advisory Board since April 2013. He serves as a Director of Nventa Biopharmaceuticals Corporation. He serves as a Member of Scientific Advisory Board at GrassRoots Biotechnology Inc. Dr. Young served as a Director of Enzon Pharmaceuticals Inc. from April 19, 2010 to November 20, 2013. He serves as a Member of the Whitehead Institute for Biomedical Research. His honors include a Burroughs Wellcome Scholarship, the Chiron Corporation Biotechnology Research Award, Yale's Wilbur Cross Medal and Scientific American recognized him as one of the top 50 leaders in science, technology and business in 2006. Dr. Young has been associated with a number of biotechnology, pharmaceutical and other companies. Dr. Young received his B.S. degree in Biological Sciences at Indiana University and his Ph.D. in Molecular Biophysics and Biochemistry at Yale University. He received postdoctoral training at the Swiss Institute for Experimental Cancer Research and at Stanford University School of Medicine.

Dr. David A. Roth, M.D. has been Chief Medical Officer at Syros Pharmaceuticals, Inc. since December 07, 2015. Dr. Roth served as Chief Medical Officer and Executive Vice President of Infinity Pharmaceuticals, Inc. from January 2014 to September 11, 2015. He served as Senior Vice President of Clinical Development & Medical Affairs at Infinity Pharmaceuticals, Inc. from September 2013 to February 4, 2014. Dr. Roth is responsible for the clinical development organization and clinical operations and build and oversees the medical affairs function. He has over 20 years of experience in hematology and oncology research and development. He holds a distinguished track record spanning both industry and academia. Dr. Roth Joined Infinity in 2013. Dr. Roth joined Infinity following more than ten years with Pfizer Inc. and Wyeth Pharmaceuticals. At Pfizer, he served as a Interim Co-head of Clinical Development and Vice President of Early Development in Pfizer's oncology business unit. Dr. Roth joined Pfizer from Wyeth, where he held the role of Assistant Vice President of clinical research & development and global therapeutic area director of hematology. While at Pfizer and Wyeth, Dr. Roth contributed to the successful regulatory approval of several products, including Bosulif(R) (bosutinib), a dual Src/Abl tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia, Xyntha(R) and ReFacto AF(R) for the treatment of hemophilia A and BeneFIX(R) for the treatment of hemophilia B. Dr. Roth also led the early development of palbociclib, a CDK 4/6 inhibitor, to Phase 3 evaluation in women with ER positive advanced breast cancer. During his tenure at Pfizer and Wyeth, Dr. Roth also co-chaired Pfizer's oncology research and development board and served on several oncology and hematology R&D leadership teams and governance committees. He serves as a full-time faculty at Harvard Medical School and Beth Israel Deaconess Medical Center in the Division of Hematology/Oncology. In addition to his extensive industry experience, he is an accomplished academic researcher and clinical practitioner. He completed his fellowship in hematology and oncology at Tufts-New England Medical Center and his Internal Medicine residency at the New England Deaconess Hospital in Boston. Dr. Roth received his BS from the Massachusetts Institute of Technology and his M.D. from Harvard Medical School in the Harvard-M.I.T. Division of Health Sciences and Technology where he remains on the Affiliated Faculty.

Kristin Stephens serves as the Senior Vice President, Product Development of Syros Pharmaceuticals. Kristin started at Syros Pharmaceuticals in Aug of 2018. Kristin currently resides in the Greater Boston Area.

Tiffany Crowell serves as the Vice President, Clinical Operations of Syros Pharmaceuticals. Tiffany started at Syros Pharmaceuticals in Oct of 2018. Tiffany currently resides in the Greater Boston Area.

Joseph Ferra serves as the Chief Financial Officer of Syros Pharmaceuticals. Joseph started at Syros Pharmaceuticals in March of 2018. Joseph currently resides in the Greater Boston Area.

Gerald Quirk serves as the Chief Legal & Administrative Officer of Syros Pharmaceuticals. Gerald started at Syros Pharmaceuticals in September of 2016. Gerald currently resides in the Greater Boston Area.